Medicine and Dentistry
Uterine Cancer
100%
Gynecological Oncology
36%
Neoplasm
33%
Ovarian Cancer
29%
Progression Free Survival
27%
Oncology
26%
Hysterectomy
23%
Overall Survival
22%
Krukenberg Tumor
21%
Recurrent Disease
19%
Female Genital Tract Cancer
18%
DNA Mismatch Repair
16%
Diseases
15%
Cancer
14%
Malignant Neoplasm
14%
Cervical Cancer
14%
Clinical Trial
13%
Pembrolizumab
12%
Body Mass Index
11%
Hereditary Nonpolyposis Colorectal Cancer
10%
Bevacizumab
9%
Chemotherapy
8%
Disease
8%
Endometrium Carcinoma
8%
Retroperitoneal Lymph Node Dissection
8%
Postoperative Complication
8%
Sentinel Lymph Node
8%
Paclitaxel
7%
PARP Inhibitor
7%
Laparotomy
7%
Cisplatin
7%
Robot-Assisted Surgery
7%
Radiation Therapy
7%
Placebo
6%
Pelvic Exenteration
6%
Niraparib
6%
Risk Stratification
6%
Lymph Node
6%
Odds Ratio
6%
Metastatic Carcinoma
6%
Mismatch Repair Protein
6%
Carboplatin
6%
Protein Expression
6%
Hazard Ratio
6%
Recurrence Free Survival
5%
Cytoreductive Surgery
5%
Primary Peritoneal Cancer
5%
Neoadjuvant Chemotherapy
5%
Biological Marker
5%
Comorbidity
5%
Keyphrases
Endometrial Cancer
71%
NRG Oncology
29%
Progression-free Survival
27%
Gynecologic Oncology Group
26%
Overall Survival
26%
Tumor
20%
Group Studies
19%
Ovarian Cancer
18%
Chemotherapy
17%
Confidence Interval
17%
Gynecological Cancer
16%
Recurrent Endometrial Cancer
15%
Epithelial Ovarian Cancer
15%
Robotics
12%
Gynecologic Oncology
12%
Bevacizumab
12%
Mismatch Repair
12%
Advanced Ovarian Cancer
12%
Pembrolizumab
12%
Cancer Patients
11%
Endometrioid Endometrial Cancer
11%
Lynch Syndrome
10%
Newly Diagnosed
10%
Cervical Cancer
9%
Cisplatin
8%
Uterine Cancer
8%
Gynecologic Malignancies
8%
Randomized Phase II Trial
8%
Body Mass Index
7%
Robotic Hysterectomy
7%
Carboplatin
7%
PARP Inhibitor (PARPi)
7%
Endometrial Carcinoma
7%
Niraparib
7%
Hazard Ratio
7%
Robotic Surgery
6%
Endometrioid
6%
Uterine Serous Carcinoma
6%
Pelvic Exenteration
6%
Phase II Study
6%
Recurrent Disease
6%
Median Progression-free Survival
6%
Laparotomy
6%
Protein Expression
6%
Hysterectomy
6%
Recurrence-free Survival
6%
Minimally Invasive Hysterectomy
6%
Sentinel Lymph Node
6%
Neoadjuvant Chemotherapy
6%
Single Institution
6%